Publication date: 08/05/2017
MDxHealth SA (Euronext: MDXH.BR) today issued its first trading update for the year summarizing commercial, R&D and financial highlights for the four months ended April 30, 2017.
"With nearly 8,000 patients tested during the first four months of 2017, we experienced strong growth in volume compared to the same period last year," said Dr. Jan Groen, CEO of MDxHealth. "Additionally, we believe our recent US government services agreement, together with 11 new payor contracts, will continue to drive positive momentum through the rest of the year."
Commercial highlights (four months ended April 30, 2017):
The company maintains its guidance for the 2017 fiscal year and expects continued revenue growth from increased adoption of ConfirmMDx and SelectMDx in the EU and US markets, driven by increased payor coverage, distribution agreements for SelectMDx and launch of the SelectMDx CE-marked vitro diagnostic (IVD) kit.
The Company maintains the following guidance for 2017:
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.